NEK2 promotes the protein stability of programmed death ligand-1 (PD-L1) by phosphorylating PD-L1 at T194/T210 and reduces the efficacy of PD-L1 targeted immunotherapy in pancreatic cancer [29]. The gene discussed is CD274; the disease is familial pancreatic carcinoma.